康哲药业(00867)：创新药磷酸芦可替尼乳膏AD适应症中国三期药物临床研究取得积极结果

智通财经09-26

智通财经APP讯，康哲药业(00867)发布公告，旗下德镁医药有限公司(德镁医药，专业聚焦皮肤健康的创新型医药企业，正申请于香港联合交易所有限公司主板独立上市)连同其附属公司取得磷酸芦可替尼乳膏(芦可替尼乳膏)轻中度特应性皮炎(AD)的中国三期药物临床研究积极结果。该试验是一项在中国人群开展的随机、双盲、安慰剂对照、多中心的临床研究，共入组192例患者，旨在评估产品治疗轻中度AD的安全性和有效性。...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2570900024?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-09-26 19:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2570900024","market":"hk","top_or_hot":-1,"title":"康哲药业(00867)：创新药磷酸芦可替尼乳膏AD适应症中国三期药物临床研究取得积极结果","media":"智通财经","content":"<div>\n<p>智通财经APP讯，康哲药业(00867)发布公告，旗下德镁医药有限公司(德镁医药，专业聚焦皮肤健康的创新型医药企业，正申请于香港联合交易所有限公司主板独立上市)连同其附属公司取得磷酸芦可替尼乳膏(芦可替尼乳膏)轻中度特应性皮炎(AD)的中国三期药物临床研究积极结果。该试验是一项在中国人群开展的随机、双盲、安慰剂对照、多中心的临床研究，共入组192例患者，旨在评估产品治疗轻中度AD的安全性和有效性。...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1350045.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>康哲药业(00867)：创新药磷酸芦可替尼乳膏AD适应症中国三期药物临床研究取得积极结果</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n康哲药业(00867)：创新药磷酸芦可替尼乳膏AD适应症中国三期药物临床研究取得积极结果\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-09-26 19:33 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1350045.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，康哲药业(00867)发布公告，旗下德镁医药有限公司(德镁医药，专业聚焦皮肤健康的创新型医药企业，正申请于香港联合交易所有限公司主板独立上市)连同其附属公司取得磷酸芦可替尼乳膏(芦可替尼乳膏)轻中度特应性皮炎(AD)的中国三期药物临床研究积极结果。该试验是一项在中国人群开展的随机、双盲、安慰剂对照、多中心的临床研究，共入组192例患者，旨在评估产品治疗轻中度AD的安全性和有效性。...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1350045.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4132","symbol_name":"无线电信业务","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1350045.html","article_id":"2570900024","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2570900024","pubTimestamp":1758886425,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，康哲药业 发布公告，旗下德镁医药有限公司连同其附属公司取得磷酸芦可替尼乳膏轻中度特应性皮炎的中国三期药物临床研究积极结果。该试验是一项在中国人群开展的随机、双盲、安慰剂对照、多中心的临床研究，共入组192例患者，旨在评估产品治疗轻中度AD的安全性和有效性。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159992":"创新药","BK4132":"无线电信业务","00867":"康哲药业","AD":"Array Digital Infrastructure Inc.","BK1161":"生物科技","SG9999015978.USD":"利安颠覆性创新基金A","BK1574":"生物医药B类股","BK1191":"制药","IE00BMCWC346.EUR":"GUINNESS EMERGING MARKETS EQUITY INCOME \"C\" (EUR) ACC","SG9999015952.SGD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (SGD) ACC","SG9999015945.SGD":"LionGlobal Disruptive Innovation Fund A SGD","BK1593":"医美概念股","06978":"永泰生物-B","IE00BYV24P56.USD":"GUINNESS EMERGING MARKETS EQUITY INCOME \"C\" (USD) ACC","SG9999004220.SGD":"Nikko AM Shenton Asia Dividend Equity Fund  SGD","IE00BVYPNP33.GBP":"GUINNESS ASIAN EQUITY INCOME \"C\" (GBP) ACC","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","SG9999015986.USD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (USD) ACC","IE00BGHQDM52.EUR":"GUINNESS ASIAN EQUITY INCOME \"C\" (EUR) ACC","IE00BVYPNQ40.USD":"GUINNESS ASIAN EQUITY INCOME \"C\" (USD) ACC"},"translate_title":"CMS (00867): The innovative drug ruxolitinib phosphate cream AD indication in China's phase III drug clinical study achieved positive results","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159992":1.5,"AD":1.5,"06978":1.5,"00867":1.5},"content_text":"智通财经APP讯，康哲药业(00867)发布公告，旗下德镁医药有限公司(德镁医药，专业聚焦皮肤健康的创新型医药企业，正申请于香港联合交易所有限公司主板独立上市)连同其附属公司取得磷酸芦可替尼乳膏(芦可替尼乳膏)轻中度特应性皮炎(AD)的中国三期药物临床研究积极结果。该试验是一项在中国人群开展的随机、双盲、安慰剂对照、多中心的临床研究，共入组192例患者，旨在评估产品治疗轻中度AD的安全性和有效性。该研究组长单位为上海市皮肤病医院，主要研究者为史玉玲教授。产品用于轻中度特应性皮炎的中国三期临床研究成功达到主要终点，即使用芦可替尼乳膏治疗8周，达到研究者整体评估(IGA)评分为0或1分，且较基线改善≥2分的受试者比例，显著高于安慰剂(63.0% vs 9.2%，P<0.001)。关键次要终点，芦可替尼乳膏治疗8周达到湿疹面积及严重程度指数评分较基线至少改善75%(EASI 75)的受试者比例亦显著优于安慰剂(78.0% vs 15.4%，P<0.001)。安全性方面，治疗期出现的不良事件(TEAE)的严重程度大多数为轻度或中度，未发生导致研究药物用药终止的治疗期出现的不良事件(TEAE)，整体安全耐受性良好。此外，集团正积极推进产品在中国的新药上市申请(NDA)工作。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.10","shortVersion":"4.35.10","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2570900024","isCrawlerRequest":true}